{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:45:20Z","timestamp":1772163920435,"version":"3.50.1"},"reference-count":27,"publisher":"BMJ","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Humanigen, Inc","award":["No grant number is associated with for this compan"],"award-info":[{"award-number":["No grant number is associated with for this compan"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>COVID-19 severity is correlated with granulocyte macrophage colony-stimulating factor (GM-CSF) and C reactive protein (CRP) levels. In the phase three LIVE-AIR trial, lenzilumab an anti-GM-CSF monoclonal antibody, improved the likelihood of survival without ventilation (SWOV) in COVID-19, with the greatest effect in participants having baseline CRP below a median of 79 mg\/L. Herein, the utility of baseline CRP to guide lenzilumab treatment was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A subanalysis of the randomised, blinded, controlled, LIVE-AIR trial in which lenzilumab or placebo was administered on day 0 and participants were followed through Day 28.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Hospitalised COVID-19 participants (N=520) with SpO2 \u226494% on room air or requiring supplemental oxygen but not invasive mechanical ventilation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Lenzilumab (1800 mg; three divided doses, q8h, within 24 hours) or placebo infusion alongside corticosteroid and remdesivir treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The primary endpoint was the time-to-event analysis difference in SWOV through day 28 between lenzilumab and placebo treatments, stratified by baseline CRP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SWOV was achieved in 152 (90%; 95% CI 85 to 94) lenzilumab and 144 (79%; 72 to 84) placebo-treated participants with baseline CRP &lt;150 mg\/L (HR: 2.54; 95% CI 1.46 to 4.41; p=0.0009) but not with CRP \u2265150 mg\/L (HR: 1.04; 95% CI 0.51 to 2.14; p=0.9058). A statistically significant interaction between CRP and lenzilumab treatment was observed (p=0.044). Grade \u22653 adverse events with lenzilumab were comparable to placebo in both CRP strata. No treatment-emergent serious adverse events were attributed to lenzilumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Hospitalised hypoxemic patients with COVID-19 with baseline CRP &lt;150 mg\/L derived the greatest clinical benefit from treatment with lenzilumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04351152\">NCT04351152<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thoraxjnl-2022-218744","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T12:49:35Z","timestamp":1657889375000},"page":"thoraxjnl-2022-218744","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 \u2018LIVE-AIR\u2019 trial"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"nct04351152","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zelalem","family":"Temesgen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen F","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Cerasoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Kilcoyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Durrant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Catterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Polk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Badley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent C","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"2022071509252189000_thoraxjnl-2022-218744v1.1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg9873"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.2","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwaa041"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17052"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.4","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1747363"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1042\/bj3250617","article-title":"Interleukin-6 is necessary, but not sufficient, for induction of the humanC-reactive protein gene in vivo","volume":"325 (Pt 3)","author":"Weinhold","year":"1997","journal-title":"Biochem J"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.16.9503"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.7","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-020-00798-x"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1966"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.9","doi-asserted-by":"crossref","unstructured":"Hodges G , Pallisgaard J , Schjerning Olsen A-M , et al . Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohort study. BMJ Open 2020;10:e041295.doi:10.1136\/bmjopen-2020-041295","DOI":"10.1136\/bmjopen-2020-041295"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30275-7"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.11","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.3497"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-021-00464-w"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cell.2020.08.020","article-title":"Patrolling alveolar macrophages conceal bacteria from the immune system to maintain homeostasis","volume":"183","author":"Neupane","year":"2020","journal-title":"Cell"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00494-X"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108614"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173547"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.18","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02646-9"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.19","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.4049\/jimmunol.160.11.5294","article-title":"Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice","volume":"160","author":"Szalai","year":"1998","journal-title":"J Immunol"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.09.021"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.23","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.2209"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.24","unstructured":"National Institutes of Health . COVID-19 treatment guidelines: interleukin-6 inhibitors, 2021. Available: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/immunomodulators\/interleukin-6-inhibitors\/ [Accessed 18 Aug 2021]."},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041295"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30559-2"},{"key":"2022071509252189000_thoraxjnl-2022-218744v1.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3339"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2022-218744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T13:23:14Z","timestamp":1676121794000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2022-218744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":27,"alternative-id":["10.1136\/thoraxjnl-2022-218744"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2022-218744","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.30.21267140","asserted-by":"object"}]},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}